Healthcare | November 18, 2022
Zydus Lifesciences gets exclusive marketing rights for CanAssist Breast
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
The CRL did not identify any outstanding scientific issues with the product.
Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
The award recognizes Parexel for delivering the best decentralized trial experience for customers through its capabilities, expertise, and patient recruitment and retention strategies
Subscribe To Our Newsletter & Stay Updated
